Astra will buy EsoBiotec for up to £770m comprised of an initial £327m payment and another £443m in the future if it hits ...

The European Commission approves AstraZeneca's Imfinzi for treating patients with limited-stage small-cell lung cancer based ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

Warren Buffett's Berkshire Hathaway (BRK-B) has increased its stakes in Japan's largest trading houses, according to reports.

Imfinzi has been approved in the European Union as monotherapy for the treatment of adults with limited-stage small cell ...

The Cambridge-based pharmaceuticals maker has agreed to pay up to USD1 billion for EsoBiotec SA on a cash and debt free basis. This includes an initial payment of USD425 million on deal closing, and ...

In early UK corporate news, Phoenix Group lifted its 2026 profit outlook after meeting a cash generation goal sooner than expected. AstraZeneca announced a USD1 billion acquisition. Elsewhere, there ...

Approval based on ADRIATIC Phase III trial results which showed a 27% reduction in the risk of death versus placebo ...

The safety profile for Imfinzi was generally manageable and consistent with the known profile of this medicine.